ReviewFrontiers in bioengineering and biotechnology2020
Bioengineering of Pulmonary Epithelium With Preservation of the Vascular Niche.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Decellularized Rat Lung Extracellular Matrix as an In Vitro Platform for Canine Yolk Sac-Derived Endothelial Precursor Cells for Pulmonary Endothelium Reconstruction Studies.Bioengineering (Basel, Switzerland) · 2026Article
- Anti-CD31 antibody preconditioning for enhancement of endothelial cell capture and vascularization: a novel strategy for bioengineering lung scaffolds.Journal of biological engineering · 2026Article
- Nanomedicines via the pulmonary route: a promising strategy to reach the target?Drug delivery and translational research · 2024Review
- Advances in lung bioengineering: Where we are, where we need to go, and how to get there.Frontiers in transplantation · 2023Review
- Mimicking the Natural Basement Membrane for Advanced Tissue Engineering.Biomacromolecules · 2022Review
- Harnessing organs-on-a-chip to model tissue regeneration.Cell stem cell · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The shortage of transplantable donor organs directly affects patients with end-stage lung disease, for which transplantation remains the only definitive treatment. With the current acceptance rate of donor lungs of only 20%, rescuing even one half of the rejected donor lungs would increase the number of transplantable lungs threefold, to 60%. We review recent advances in lung bioengineering that have potential to repair the epithelial and vascular compartments of the lung. Our focus is on the long-term support and recovery of the lung
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.